216 research outputs found

    Temporal Trends in Pancreatic Cancer

    Get PDF

    Combined treatment of pancreatic cancer - current strategies

    Get PDF
    W┼Ťr├│d chor├│b nowotworowych jedn─ů z najcz─Östszych przyczyn zgon├│w jest rak trzustki. Wsp├│┼éczynniki zachorowalno┼Ťci na raka trzustki s─ů w┼éa┼Ťciwie r├│wne wsp├│┼éczynnikom umieralno┼Ťci, co ┼Ťwiadczy o szczeg├│lnie niekorzystnym rokowaniu. Obecnie jedyn─ů szans─ů wyleczenia jest zabieg resekcyjny, jednak usuni─Öcie nowotworu jest mo┼╝liwe tylko u oko┼éo 20-30% chorych. W ci─ůgu ostatnich dziesi─Öcioleci odsetki prze┼╝y─ç 5-letnich po zabiegach resekcyjnych wykazywa┼éy tendencj─Ö wzrostow─ů, ale nadal wynosz─ů jedynie oko┼éo 10-30% z median─ů prze┼╝ycia si─Ögaj─ůc─ů 15-20 miesi─Öcy. Poza wzrastaj─ůc─ů liczb─ů zabieg├│w resekcyjnych, centralizacja leczenia operacyjnego chorych na raka trzustki w o┼Ťrodkach dysponuj─ůcych odpowiednim do┼Ťwiadczonym personelem pozwoli┼éa zmniejszy─ç ryzyko powik┼éa┼ä i wsp├│┼éczynnik ┼Ťmiertelno┼Ťci pooperacyjnej. W ┼Ťwietle wynik├│w dotychczasowych bada┼ä klinicznych konieczne jest wdro┼╝enie programu kompleksowego leczenia skojarzonego, w kt├│rym chemioterapia lub chemioradioterapia s─ů nieroz┼é─ůcznym uzupe┼énieniem zabieg├│w chirurgicznych. Mimo wielu entuzjastycznych doniesie┼ä nadal nie opracowano optymalnego modelu leczenia skojarzonego chorych z rakiem trzustki, a r├│┼╝nice obserwowane mi─Ödzy wynikami poszczeg├│lnych bada┼ä wskazuj─ů na konieczno┼Ť─ç przeprowadzenia dalszych, odpowiednio zaprojektowanych bada┼ä klinicznych z udzia┼éem du┼╝ych populacji chorych.Pancreatic cancer is one of the most common causes of cancer-related death. The prognosis, as indicated by nearly equal incidence and mortality rates, is very poor. Although the only chance for cure is currently pancreatic resection, the tumour can be removed only in about 20-30% of patients. Five-year survival rates reported in recent decades have demonstrated an increasing trend, but the 5-year survival is still only about 10-30% with the median survival of 15-20 months. A rising number of pancreatic resections along with centralisation of pancreatic cancer surgery in hospitals with adequately trained personnel resulted in reduced rates of morbidity and postoperative mortality. Previous clinical trials have emphasised the need for a combined treatment where chemotherapy or chemoradiotherapy are inseparably associated with surgical interventions. Though many enthusiastic studies have been reported, the optimal regimen of the combined therapy has not been agreed. Moreover, the differences observed between individual studies suggest that further well-designed clinical trials involving large patient populations are necessary

    5 Temporal Trends in Pancreatic Cancer

    Get PDF

    The effectiveness of Penumbra 400 micro-coils in the embolization of large cerebral aneurysms

    Get PDF
    Background: The objective of this work is to analyze the effectiveness of Penumbra 400 micro -coils in the embolization of large cerebral aneurysms. Material and methods: A retrospective analysis has been conducted in a group of 32 patients at the average age of 54.5 years (30-84) for whose embolization the P400 micro-coils (P400) have been used. A control group consisted of 44 patients at the average age of 52.7 years (24ÔÇô82) in whose aneurysm embolization the 18 micro-coils (MC) have been utilized. Results: The respective percentages of micro-coil packing density in aneurysm sacs were 31.5% for P400 and 29% for MC. The average P400 fluoroscopy time was 21 min, and 34 min in case of MC. The average number of used micro-coils was 3.9 for P400 and 5.6 for MC. The radiation dose received by a patient was 1.7 Gy/2.2 Gy, respectively. The recanalization of P400 has occurred in 14/31 cases (45%), and for MC it has occurred in 23/44 (52%) patients. One patient died due to early recanalization after P400 aneurysm embolization. Conclusion: Procedures with use of the P400 demonstrate minimally higher effectiveness of large aneurysms embolization in comparison with the MS with a not much shorter duration and reduction of a radiation dose that a patient receives
    • ÔÇŽ
    corecore